BSN HESI 315 Pharmacology GUIDE Exam New 2026/2027 | Questions & Answers with Detailed Rationales | 100% Correct Grade A | HESI & NCLEX-RN® Pharmacology Review PDF

INSTANT PDF DOWNLOAD — This is the comprehensive Pharmacology GUIDE Exam preparation guide for BSN HESI 315 (New 2026/2027), featuring questions and answers with detailed rationales. Designed for nursing students preparing for the HESI Pharmacology Exam and NCLEX-RN®, this resource consolidates the essential pharmacology concepts required to achieve a high score on the HESI Pharmacology exam and pass the NCLEX-RN® on the first attempt. The guide is meticulously aligned with HESI testing blueprints, NCLEX-RN® test plan, and current evidence-based pharmacology standards. This verified resource provides comprehensive coverage of key HESI Pharmacology exam topics, including: Pharmacokinetics (absorption—bioavailability, first-pass effect (oral medications metabolized by liver before reaching systemic circulation, reduced bioavailability, alternative routes (IV, IM, sublingual, rectal) bypass first-pass), factors affecting absorption (route of administration (IV fastest), blood flow, pain/stress, food, pH, surface area, motility), distribution—volume of distribution (high Vd: drug distributes to tissues, long half-life (digoxin, amiodarone); low Vd: remains in plasma, short half-life (warfarin)), protein binding (highly protein-bound drugs (90%): warfarin (99%), phenytoin (90-95%), valproate (90%), ceftriaxone (85-95%), diazepam (99%), only free (unbound) drug active, drug-drug displacement interactions (warfarin + phenytoin, warfarin + valproate, warfarin + sulfonamides increase free drug, toxicity risk), blood-brain barrier (lipid-soluble drugs cross (benzodiazepines, opioids, antipsychotics, antidepressants), P-glycoprotein efflux pump), placental transfer (lipid-soluble, low molecular weight drugs cross (opioids, benzodiazepines, anticonvulsants, alcohol, nicotine), teratogenic risk highest first trimester), metabolism—liver (phase I (CYP450 system—oxidation, reduction, hydrolysis), phase II (conjugation—glucuronidation, acetylation, sulfation), CYP450 inducers (increase metabolism, decrease drug levels—rifampin, carbamazepine, phenytoin, phenobarbital, St. John's wort, smoking), CYP450 inhibitors (decrease metabolism, increase drug levels, risk toxicity—ketoconazole, itraconazole, clarithromycin, erythromycin, ritonavir, grapefruit juice, amiodarone, verapamil, diltiazem, cimetidine, fluconazole, omeprazole, fluoxetine, paroxetine, bupropion), genetic polymorphisms (CYP2D6 poor metabolizers: codeine ineffective, increased toxicity for metoprolol, carvedilol, haloperidol; CYP2D6 ultrarapid metabolizers: codeine toxicity (respiratory depression, death), contraindicated in breastfeeding; CYP2C19 poor metabolizers: clopidogrel resistance (increased stent thrombosis, MI, stroke); CYP2C9 poor metabolizers: warfarin sensitivity (reduce dose, monitor INR)), elimination—renal (glomerular filtration, tubular secretion, tubular reabsorption, drug interactions affecting renal elimination (NSAIDs + lithium (increased lithium levels, toxicity), ACEi/ARB + lithium, diuretics + lithium), half-life (time for drug concentration to decrease by 50%, determines dosing interval), steady state (reached after 4-5 half-lives, loading dose for drugs with long half-life (digoxin, amiodarone, phenytoin, warfarin)), therapeutic drug monitoring (indications: narrow therapeutic index (digoxin, lithium, phenytoin, valproate, carbamazepine, theophylline, aminoglycosides, vancomycin, cyclosporine, tacrolimus, warfarin (INR)), variable pharmacokinetics, non-adherence, toxicity), therapeutic index (TI = TD50/ED50, low TI (narrow therapeutic window, need monitoring: digoxin, lithium, phenytoin, warfarin, theophylline, aminoglycosides, vancomycin)), pharmacodynamics (receptor theory—agonist (activates receptor—albuterol (beta-2 agonist), morphine (mu-opioid agonist)), partial agonist (submaximal response—buprenorphine, aripiprazole), antagonist (blocks receptor—naloxone, flumazenil, metoprolol, losartan), potency (dose required for 50% of maximal effect (ED50), lower ED50 = more potent (fentanyl more potent than morphine)), efficacy (maximal effect (Emax), ceiling effect (ibuprofen analgesic ceiling 400-600 mg)), tolerance (decreased response over time, need higher dose (opioids, benzodiazepines, nicotine, alcohol)), dependence (physiological adaptation, withdrawal symptoms when stopped), addiction (psychological craving, compulsive use despite harm), adverse drug reactions—Type A (augmented, dose-dependent, predictable (anticholinergic effects (dry mouth, constipation, urinary retention, blurred vision, tachycardia, cognitive impairment), bleeding (anticoagulants, antiplatelets), hypoglycemia (insulin, sulfonylureas), orthostatic hypotension (alpha-blockers, TCAs), QT prolongation (amiodarone, sotalol, methadone, haloperidol (IV), ziprasidone, citalopram, levofloxacin, moxifloxacin, azithromycin, ondansetron—risk torsades de pointes, avoid with hypokalemia, hypomagnesemia, bradycardia, other QT-prolonging drugs)), Type B (bizarre, idiosyncratic, unpredictable—anaphylaxis (penicillin, sulfa drugs, latex, contrast media), Stevens-Johnson syndrome/TEN (allopurinol, carbamazepine, phenytoin, lamotrigine, sulfonamides, NSAIDs), DRESS (allopurinol, carbamazepine, phenytoin, lamotrigine, sulfonamides, vancomycin, minocycline)), Type C (continuous, long-term use—corticosteroid-induced osteoporosis, adrenal suppression, growth suppression, Cushing's syndrome; NSAID-induced gastric ulcer), Type D (delayed, time-related—tardive dyskinesia (antipsychotics, metoclopramide, prochlorperazine, promethazine), after months to years, potentially irreversible, prevention (lowest effective dose, shortest duration, regular AIMS monitoring), treatment (valbenazine (Ingrezza), deutetrabenazine (Austedo) VMAT2 inhibitors)), Type E (end of treatment, withdrawal—benzodiazepine withdrawal (anxiety, insomnia, seizures, delirium tremens-like, life-threatening, taper over weeks to months), opioid withdrawal (not life-threatening but severe (yawning, rhinorrhea, piloerection, mydriasis, muscle aches, abdominal cramps, nausea, vomiting, diarrhea, tachycardia, hypertension, fever, diaphoresis, insomnia, anxiety, craving), treatment (methadone, buprenorphine, clonidine, lofexidine)), corticosteroid withdrawal (adrenal insufficiency—fatigue, weakness, nausea, vomiting, hypotension, hypoglycemia, hyponatremia, hyperkalemia, taper slowly, stress dose for surgery/illness), beta-blocker withdrawal (rebound hypertension, tachycardia, angina, MI, arrhythmias, sudden death, taper over 1-2 weeks), clonidine withdrawal (rebound hypertension, tachycardia, agitation, anxiety, headache, nausea, vomiting, life-threatening hypertensive crisis, taper over 2-7 days)), drug interactions—pharmacodynamic (additive (opioid + benzodiazepine (respiratory depression), alcohol + benzodiazepine (CNS depression), ACEi + ARB (hyperkalemia, hypotension, renal impairment)), synergistic (TMP-SMX (trimethoprim + sulfamethoxazole), piperacillin + tazobactam)), antagonistic (naloxone + morphine, vitamin K + warfarin)), pharmacokinetic—absorption (antacids decrease absorption of tetracyclines, fluoroquinolones, bisphosphonates, iron, levothyroxine—separate by 2-4 hours), distribution (protein-binding displacement (warfarin + phenytoin, warfarin + valproate, warfarin + sulfonamides, phenytoin + valproate—monitor INR, levels, toxicity)), metabolism (CYP450 inducers: rifampin + oral contraceptives (unintended pregnancy), rifampin + warfarin (decreased INR, thrombosis), carbamazepine/phenytoin/phenobarbital + warfarin, carbamazepine/phenytoin/phenobarbital + oral contraceptives, St. John's wort + oral contraceptives, St. John's wort + warfarin, St. John's wort + cyclosporine/tacrolimus (graft rejection), smoking + theophylline, smoking + olanzapine, clozapine, haloperidol (smokers need higher doses), CYP450 inhibitors: clarithromycin/erythromycin + simvastatin/atorvastatin/lovastatin (increased statin levels, myopathy, rhabdomyolysis, avoid or use pravastatin, rosuvastatin, fluvastatin, pitavastatin), clarithromycin/erythromycin + colchicine (increased colchicine levels, GI toxicity, myopathy, neuropathy, pancytopenia, avoid or reduce colchicine dose), grapefruit juice + simvastatin/atorvastatin/lovastatin (increased levels, myopathy, rhabdomyolysis, avoid grapefruit juice), fluconazole + warfarin (increased INR, bleeding, monitor INR, reduce warfarin dose), fluconazole + phenytoin (increased phenytoin levels, nystagmus, ataxia, drowsiness), valproate + lamotrigine (valproate doubles lamotrigine levels, increased risk serious rash (SJS/TEN), start lamotrigine at half dose when adding to valproate), amiodarone + warfarin (increased INR, bleeding, reduce warfarin dose by 30-50%, monitor INR closely), amiodarone + digoxin (increased digoxin levels, toxicity (nausea, vomiting, visual changes, bradycardia, arrhythmias), reduce digoxin dose by 50%, monitor levels), cimetidine + warfarin (increased INR, bleeding, use famotidine or ranitidine (no CYP inhibition)), fluoxetine/paroxetine/bupropion + tamoxifen (CYP2D6 inhibition, reduced tamoxifen activation to endoxifen, increased breast cancer recurrence risk, avoid these antidepressants in breast cancer patients on tamoxifen, use sertraline, citalopram, escitalopram, venlafaxine, duloxetine, mirtazapine), omeprazole + clopidogrel (omeprazole inhibits CYP2C19, reduces clopidogrel activation, increased risk stent thrombosis, MI, stroke, avoid omeprazole and esomeprazole, use pantoprazole, lansoprazole, rabeprazole (less CYP2C19 inhibition) or H2RA (famotidine, ranitidine) but not cimetidine)), elimination (NSAIDs + lithium (increased lithium levels, toxicity, avoid NSAIDs in patients on lithium, use acetaminophen), ACEi/ARB + lithium (increased lithium levels, toxicity, monitor levels, reduce dose), loop/thiazide diuretics + lithium (increased lithium levels, toxicity, monitor levels, maintain hydration), loop diuretics + aminoglycosides (increased risk ototoxicity, nephrotoxicity, avoid if possible, monitor renal function, audiometry), vancomycin + piperacillin/tazobactam (increased risk acute kidney injury, avoid if possible, monitor Cr daily), digoxin + verapamil (verapamil decreases digoxin renal clearance, increases digoxin levels, toxicity, reduce digoxin dose by 50% when adding verapamil, monitor levels), digoxin + amiodarone (increased digoxin levels, toxicity, reduce digoxin dose by 50%, monitor levels), digoxin + spironolactone (increased digoxin levels, toxicity, monitor levels), digoxin + erythromycin/clarithromycin (macrolides increase digoxin levels (kill gut bacteria that metabolize digoxin), monitor levels, reduce digoxin dose if needed), digoxin + itraconazole/ketoconazole (increased digoxin levels, monitor), digoxin + quinidine (increased digoxin levels 2-3 fold, toxicity, reduce digoxin dose by 50-75% when adding quinidine, monitor levels)), medication administration (oral—check for swallowing ability, crush only if scored or immediate-release, not enteric-coated (EC) or extended-release (ER, SR, CR, LA, XL, XR, CD, SA)—crushing bypasses coating, releases all drug at once, risk overdose, toxicity, death (nifedipine ER, verapamil ER, diltiazem ER, morphine ER, oxycodone ER, hydromorphone ER, bupropion XL (seizure risk), venlafaxine XR (risk withdrawal), duloxetine, lithium ER, divalproex ER, carbamazepine ER, phenytoin ER, potassium chloride ER (risk gastric ulcer, perforation)), sublingual (under tongue—nitroglycerin, buprenorphine, asenapine), buccal (between cheek and gum—fentanyl, buprenorphine, prochlorperazine, ondansetron), intranasal (spray—sumatriptan, zolmitriptan, butorphanol, naloxone, desmopressin, calcitonin), topical—transdermal patch (fentanyl, buprenorphine, nitroglycerin, clonidine, scopolamine, estradiol, testosterone), apply to clean, dry, intact skin, rotate sites, avoid skin folds, shaved areas, not on inflamed/irritated/broken skin, wash hands before and after, do not cut patch (unless scored), remove old patch before applying new, dispose by folding adhesive side together, for fentanyl patch onset 12-24 hours, duration 48-72 hours, do not apply external heat (heating pad, electric blanket, hot tub, sauna, fever) increases absorption, risk overdose, death, ophthalmic—eye drops, apply to lower conjunctival sac, not directly onto cornea, avoid touching tip to eye, wait 5-15 minutes between different eye drops, apply ointment last, nasolacrimal occlusion (close eye, press finger on inner canthus for 1-2 minutes, reduces systemic absorption, especially for beta-blockers (timolol) to prevent bradycardia, hypotension, bronchospasm), otic—ear drops, warm to body temperature to avoid vertigo, adult (pull pinna up and back), child 3 years (pull pinna down and back), remain on side for 2-5 minutes, rectal—suppositories/enemas, left Sim's position, insert past internal sphincter (adult 3-4 inches), hold buttocks together for 5-15 minutes (suppository) or as long as possible (enema), vaginal—suppositories, cream, tablet, ring, insert applicator, supine with knees bent), IV therapy (peripheral IV insertion—vein selection (cephalic, basilic, median cubital, dorsal hand veins), tourniquet application, site cleansing (chlorhexidine or alcohol), insertion angle 10-30 degrees, flashback indicates entry, advance catheter, withdraw needle, secure with dressing, flush with saline), IV complications—infiltration (coolness, swelling, pallor, leakage, pain, stop infusion, elevate extremity, warm/cold compress), extravasation (vesicant medications cause tissue necrosis—stop infusion, aspirate, antidote per protocol (phentolamine for norepinephrine, dopamine; hyaluronidase for vinca alkaloids, etoposide, taxanes; sodium thiosulfate for mechlorethamine; topical DMSO for anthracyclines), phlebitis (redness, warmth, tenderness, palpable cord, stop infusion, remove IV, warm compress, monitor for infection), infection (purulent drainage, fever, chills, blood cultures, antibiotics, remove IV), IV push (administer slowly over 1-5 minutes depending on medication, flush between incompatible medications, monitor for adverse reactions), intermittent IV infusion (piggyback, secondary line, flush before and after), continuous IV infusion (primary line, rate by pump or gravity, monitor drip chamber, change tubing per facility policy (every 72-96 hours, sooner for blood, lipids, propofol)), dosage calculations (dimensional analysis, ratio-proportion, formula method (desired/have × volume), dose by weight (mg/kg), IV infusion rate (mL/hr), drop factor (gtt/min = (volume × drop factor)/time in minutes), macrodrip (10-20 gtt/mL), microdrip (60